

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Complete if Known

Application Number 09/754775
Filing Date January 4, 2001
First Named Inventor Grainger, David
Group Art Unit 1617
Examiner Name Theodore Criares

TECH CENTER 1600/2900

Sheet 1 of 4

Attorney Docket No: 00295.009US3

APR 25 2002

RECEIVED

US PATENT DOCUMENTS

Examiner Initial *	Document Number	Date	Name of Patentee or Applicant of Document	Class	Subclass	Filing Date
JK	4,282,246	08/04/1981	Holland	424	275	03/07/1980
	4,287,190	09/01/1981	Boettcher et al.	424	230	11/29/1979
	4,310,523	01/12/1982	Neumann	424	240	10/10/1980
	4,317,915	03/02/1982	Confalone et al.	549	68	01/14/1980
	4,382,143	05/03/1983	Shepherd	549	68	07/23/1979
	4,428,963	01/31/1984	Confalone et al.	424	275	03/10/1983
	4,440,754	04/03/1984	Sorenson	424	140	05/23/1980
	4,629,694	12/16/1986	Harpel	435	7	07/12/1983
	4,758,555	07/19/1988	Sorenson	514	186	12/08/1986
	4,767,758	08/30/1988	Breccia et al.	514	231.5	02/26/1987
	4,952,607	08/28/1990	Sorenson	514	589	01/30/1986
	4,999,347	03/12/1991	Sorenson	514	159	10/20/1989
	5,082,834	01/21/1992	Sorenson	514	159	09/18/1990
	5,118,791	06/02/1992	Burnier et al.	530	326	06/13/1991
	5,280,040	01/18/1994	Labroo et al.	514	422	03/11/1993
	5,332,576	07/26/1994	Mantelle	424	443	05/21/1993
	5,420,243	05/30/1995	Ogawa et al.	530	324	01/26/1993
	5,451,603	09/19/1995	Piggott	514	422	03/11/1993
	5,453,492	09/26/1995	Bützow et al.	530	413	07/28/1993
	5,480,903	01/02/1996	Piggott	514	422	04/17/1994
	5,482,851	01/09/1996	Derynck et al.	435	240.1	11/05/1993
	5,484,797	01/16/1996	Bryant et al.	514	319	04/21/1995
	5,521,172	05/28/1996	Bryant et al.	514	212	08/15/1995
	5,552,433	09/03/1996	Bryant et al.	514	443	08/15/1995
	5,556,876	09/17/1996	Bryant et al.	514	443	08/15/1995
	5,610,168	03/11/1997	Draper	514	333	04/14/1995
	5,641,790	06/24/1997	Draper	514	333	04/14/1995
	5,658,883	08/19/1997	Ogawa et al.	514	12	03/08/1995
	5,658,951	08/19/1997	Magarian et al.	514	596	06/07/1995
	5,686,476	11/11/1997	May	514	324	03/15/1995
	5,688,813	11/18/1997	Sall et al.	514	324	04/14/1995
	5,747,510	05/05/1998	Draper	514	333	01/27/1997
	5,773,479	06/30/1998	Grainger et al.	514	651	11/21/1995
	5,824,647	10/20/1998	Postlethwaite et al.	514	13	06/01/1995
	6,166,090	12/26/2000	Grainger et al.	514	651	11/06/1997
	6,197,789	03/06/2001	Grainger et al.	514	319	06/07/1996
	6,251,920	06/26/2001	Grainger et al.	514	319	05/21/1998
	6,262,079	07/17/2001	Grainger et al.	514	319	05/06/1999

EXAMINER

[Signature]

DATE CONSIDERED

11/25/02

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)



Complete if Known

Application Number 09/754775
Filing Date January 4, 2001
First Named Inventor Grainger, David
Group Art Unit 1617
Examiner Name Theodore Criares

TECH CENTER 1600/2900

Sheet 2 of 4

Attorney Docket No: 00295.009US3

APR 25 2002

RECEIVED

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Class	Subclass	T ²
TR	EP 0 002 341	06/13/1979	C07C	65/10	
	EP 0 024 096	02/25/1981	C07F	1/08	
	EP 0 302 034	02/01/1989	C08B	37/10	
	EP 0 659 418	06/28/1995	A61K	31/445	
	JP 9255570	03/21/1996	A61K	31/35	Abstract
	JP 6025288	02/01/1994			Abstract
	JP 59042375	03/08/1984	C07D	333/32	Abstract
	GB 1,587,084	03/25/1981			
	WO 85/00107	01/17/1985	A61K	31/13	Full
	WO 94/20098	09/15/1994	A61K	31/40	
	WO 94/20099	09/15/1994	A61K	31/40	
	WO 94/26303	11/24/1994	A61K	39/00	
	WO 94/26888	11/24/1994	C12N	15/11	
	WO 94/28721	12/22/1994	A01N	43/42	
	WO 95/05191	02/23/1995	A61K	38/00	
	WO 95/17095	06/29/1995	A01N	43/38	
	WO 96/07402	03/14/1996	A61K	31/075	
	WO 96/21443	07/18/1996	A61K	31/40	
	WO 96/40098	12/19/1996	A61K	31/135	

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
TR	"Health Report -- The Good News", Time, 23 (1996).
	"Heparin", In: Modern Pharmacology, Craig, C.R., et al., (eds.), Little, Brown and Company, Boston, MA, 399 (1982).
	ASCHERMANN, "Restenosis after percutaneous transluminal coronary angioplasty. Pathophysiology, new trends in prevention and treatment", Cor Vasa, 36, 211-218 (1994).
	BAGDADE et al., "Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition", J. Clinical Endocrinology and Metabolism, 70, 1132-1135 (1990).
	BAQUIAL et al., "Down-Regulation of NADPH-Diaphorase (Nitric Oxide Synthase) May Account for the Pharmacological Activities of Cu(II) ₂ (3,5-Diisopropylsalicylate) ₄ ", J. Inorganic Biochem., 60, 133-148 (1995).
	CUNNINGHAM et al., "A Study of the Structural Basis of the Carcinogenicity of Tamoxifen, Toremifene and their Metabolites", Mutation Research, 349, 85-94 (1996).
	DEALVARE et al., "Mechanism of Superoxide Anion Scavenging Reaction by Bis-(Salicylato)-Copper(II) Complex", Biochemical and Biophysical Research Communications, 69, 687-694 (1976).
	DEHMER et al., "Reduction in the Rate of Early Restenosis After Coronary Angioplasty by a Diet Supplemented with n-3 Fatty Acids", N. Engl. J. Med., 319, 733-740 (1988).

EXAMINER

[Signature]

DATE CONSIDERED

4/25/02

Substitute Disclosure Statement Form (PTO-1449)


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	09/754775
Filing Date	January 4, 2001
First Named Inventor	Grainger, David
Group Art Unit	1617
Examiner Name	Theodore Criares

Sheet 3 of 4

Attorney Docket No: 00295.009US3

TECH CENTER 1600/2900

APR 25 2002

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
✓	FRYE et al., "Oxolanosterol Oximes: Dual-Action Inhibitors of Cholesterol Biosynthesis", <u>Journal of Lipid Research</u> , 35, 1333-1344 (1994).
✓	GARG et al., "Nitric Oxide-Generating Vasodilators and 8-Bromo-Cyclic Guanosine Monophosphate Inhibit Mitogenesis and Proliferation of Cultured Rat Vascular Smooth Muscle Cells", <u>Journal of Clinical Investigation</u> , 83, 1774-1777 (1989).
✓	GOODNIGHT, "The Effects of n-3 Fatty Acids on Atherosclerosis and the Vascular Response to Injury", <u>Arch. Pathol. Lab. Med.</u> , 117, 102-106 (1993).
✓	GRAINGER, "Taking Tamoxifen To Heart", <u>Nature Medicine</u> , 1, 1226 (1995).
✓	GRAINGER et al., "Tamoxifen Elevates Transforming Growth Factor-β and Suppresses Diet-Induced Formation of Lipid Lesions in Mouse Aorta", <u>Nature Medicine</u> , 1, 1067-1073 (1995).
✓	GRIGG et al., "Determinants of Restenosis and Lack of Effect of Dietary Supplementation with Eicosapentaenoic Acid on the Incidence of Coronary Artery Restenosis After Angioplasty", <u>JACC</u> , 13, 665-672 (1989).
✓	GUETTA et al., "Effects of the Antiestrogen Tamoxifen on Low-Density Lipoprotein Concentrations and Oxidation in Postmenopausal Women", <u>The American Journal of Cardiology</u> , 76, 1072-1073 (1995).
✓	GYLLING et al., "Tamoxifen Decreases Serum Cholesterol by Inhibiting Cholesterol Synthesis", <u>Atherosclerosis</u> , 96, 245-247 (1992).
✓	KEEN et al., "Hypertension Induced Alterations in Copper and Zinc Metabolism: A Link to Vascular Disease?", In: <u>Biology of Copper Complexes</u> , Sorenson, J.R.J., (ed.), Humana Press, Clifton, New Jersey, 141-153 (1987).
✓	KURAMOCHI, "Conformational Studies and Electronic Structures of Tamoxifen and Toremifene and Their Allylic Carbocations Proposed as Reactive Intermediates Leading to DNA Adduct Formation", <u>J. Med. Chem.</u> , 39, 2877-2886 (1996).
✓	MILNER et al., "Usefulness of Fish Oil Supplements in Preventing Clinical Evidence of Restenosis After Percutaneous Transluminal Coronary Angioplasty", <u>Am. J. Cardiol.</u> , 64, 294-299 (1989).
✓	O'LEARY et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and Its Use as an Index of Antioxidant Therapy", <u>Atherosclerosis</u> , 119, 169-179 (1996).
✓	REIS et al., "Randomised Trial of Fish Oil for Prevention of Restenosis After Coronary Angioplasty", <u>The Lancet</u> , 177-181 (1989).

EXAMINER

DATE CONSIDERED

11/25/02

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)



Complete if Known	
Application Number	09/754775
Filing Date	January 4, 2001
First Named Inventor	Grainger, David
Group Art Unit	1617
Examiner Name	Theodore Criares

Sheet 4 of 4

Attorney Docket No: 00295.009US3

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
W	SAARTO et al., "Antiatherogenic Effects of Adjuvant Antiestrogens: A Randomized Trial Comparing the Effects of Tamoxifen and Toremifene on Plasma Lipid Levels in Postmenopausal Women with Node-Positive Breast Cancer", <u>Journal of Clinical Oncology</u> , <u>14</u> , 429-433 (1996).
	SORENSEN, "Pharmacological Activities of Copper Compounds", In: <u>Handbook of Metal-Ligand Interactions in Biological Fluids -- Bioinorganic Medicine</u> , <u>2</u> , Berton, G., (ed.), Marcel Dekker, Inc., New York, 1128-1139 (1995).
	VON SCHACKY et al., "Long-Term Effects of Dietary Marine ω -3 Fatty Acids upon Plasma and Cellular Lipids, Platelet Function, and Eicosanoid Formation in Humans", <u>J. Clin. Invest.</u> , <u>76</u> , 1626-1631 (1985).
	WILLIAMS et al., "The Estrogen Receptor Agonist/Antagonist Tamoxifen Inhibits Progression of Coronary Artery Atherosclerosis in Monkeys", <u>Circulation</u> , <u>92</u> , November 1995 AHA Meeting, (1995).

EXAMINER

DATE CONSIDERED

4/25/02

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached